Making robust choices: evaluating materials in your AAV process

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Making robust choices: evaluating materials in your AAV process

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

Endonucleases play a fundamental role in AAV production, though introducing novel materials into existing AAV processes can present risks. In this webinar, we will present a structured framework to assess the impact and benefits of integrating new materials like novel endonucleases into established AAV manufacturing workflows. Key evaluation criteria for new AAV manufacturing materials will also be explored.

Attendees will see comparative performance case study data of market endonucleases, focusing on critical quality attributes (CQAs) such as viral titer and residual host cell and plasmid DNA. Learn about the evaluation and potential integration of a new endonuclease into an existing AAV purification process.

See data comparing the EndoCleave with another WT endonuclease expressed in E. coli, highlighting its impact on CQAs relevant to material selection, such as titer and residual DNA levels
Learn strategies to thoroughly assess the compatibility, performance, and cost-effectiveness of new materials, process steps, and solutions before full-scale implementation, minimizing potential disruptions
Gain an understanding of critical parameters to consider when assessing the suitability of new materials for your existing AAV processes

Michael Bodo

Upstream Process Development Scientist at Spark Therapeutics, a Roche subsidiary

Michael Bodo is an Upstream Process Development Scientist at Spark Therapeutics, a Roche subsidiary. He holds a Bachelor’s of Science in Biomedical Engineering from Lehigh University with more than 7 years of industry experience in rAAV gene therapy. Michael is a skilled scientist focusing on rAAV gene therapy upstream development and manufacturing in both adherent and suspension mammalian cell systems through process characterization and commercialization

Birgit Rogell

Business Development Manager at Roche CustomBiotech

Dr Birgit Rogell is a Business Development Manager at Roche CustomBiotech EMEA LATAM, the B2B unit of Roche providing raw materials, instruments, and kits to pharma and diagnostics companies. She has a background in Biochemistry and focuses on building strong customer relationships within the mRNA and Cell & Gene Therapy manufacturing segments.